Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Incorporated on 1st December 1986, Progenics Pharmaceuticals is a biopharmaceutical company focusing on the development and commercialisation of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The company applies its expertise in clinical medicine, immunology and molecular biology to develop biopharmaceuticals to fight cancers, including malignant melanoma and prostate cancer, and viral diseases, such as HIV infection, as well as to enhance symptom management and supportive care.